One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Clifford R. Jack, Jeffrey Scott Andrews, Thomas G. Beach, Teresa Buracchio, Billy Dunn, Ana Graf, Oskar Hansson, Carole Ho, William J. Jagust, Eric McDade and 10 more
The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). The present document updates the 2018 research framework in response to several recent developments. Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine (e.g., oncology), and is becoming a unifying concept common to all neurodegenerative diseases, not just AD. The present document is consistent with this principle. Our intent is to present objective criteria for diagnosis and staging AD, incorporating recent advances in biomarkers, to serve as a bridge between research and clinical care. These criteria are not intended to provide step-by-step clinical practice guidelines for clinical workflow or specific treatment protocols, but rather serve as general principles to inform diagnosis and staging of AD that reflect current science. HIGHLIGHTS: We define Alzheimer's disease (AD) to be a biological process that begins with the appearance of AD neuropathologic change (ADNPC) while people are asymptomatic. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms. Early-changing Core 1 biomarkers (amyloid positron emission tomography [PET], approved cerebrospinal fluid biomarkers, and accurate plasma biomarkers [especially phosphorylated tau 217]) map onto either the amyloid beta or AD tauopathy pathway; however, these reflect the presence of ADNPC more generally (i.e., both neuritic plaques and tangles). An abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD and to inform clinical decision making throughout the disease continuum. Later-changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms. An integrated biological and clinical staging scheme is described that accommodates the fact that common copathologies, cognitive reserve, and resistance may modify relationships between clinical and biological AD stages.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W. J., McDade, E., Molinuevo, J. L., Okonkwo, O. C., Pani, L., Rafii, M. S., Scheltens, P., Siemers, E., Snyder, H. M., Sperling, R. A., Teunissen, C. E., & Carrillo, M. C. (2024). Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer s & Dementia, 20(8), 5143–5169. https://doi.org/10.1002/alz.13859
Jack, Clifford R., et al. "Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup." Alzheimer s & Dementia, vol. 20, no. 8, 2024, pp. 5143–5169, https://doi.org/10.1002/alz.13859.
Jack, Clifford R., Jeffrey Scott Andrews, Thomas G. Beach, Teresa Buracchio, Billy Dunn, Ana Graf, Oskar Hansson, et al. "Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup." Alzheimer s & Dementia 20, no. 8 (2024): 5143–5169. https://doi.org/10.1002/alz.13859.
Jack C. R., Andrews J. S., Beach T. G. [и др.] Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup // Alzheimer s & Dementia. — 2024. — Vol. 20, № 8. — P. 5143–5169. — URL: https://doi.org/10.1002/alz.13859
@article{jack2024revised,
title = {{Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup}},
author = {Clifford R. Jack and Jeffrey Scott Andrews and Thomas G. Beach and Teresa Buracchio and Billy Dunn and Ana Graf and Oskar Hansson and Carole Ho and William J. Jagust and Eric McDade and José Luís Molinuevo and Ozioma C. Okonkwo and Luca Pani and Michael S. Rafii and Philip Scheltens and Eric Siemers and Heather M. Snyder and Reisa Anne Sperling and Charlotte Elisabeth Teunissen and Marı́a C. Carrillo},
journal = {Alzheimer s \& Dementia},
year = {2024},
volume = {20},
number = {8},
pages = {5143--5169},
doi = {10.1002/alz.13859},
url = {https://doi.org/10.1002/alz.13859}
}TY - JOUR AU - Jack, Clifford R. AU - Andrews, Jeffrey Scott AU - Beach, Thomas G. AU - Buracchio, Teresa AU - Dunn, Billy AU - Graf, Ana AU - Hansson, Oskar AU - Ho, Carole AU - Jagust, William J. AU - McDade, Eric AU - Molinuevo, José Luís AU - Okonkwo, Ozioma C. AU - Pani, Luca AU - Rafii, Michael S. AU - Scheltens, Philip AU - Siemers, Eric AU - Snyder, Heather M. AU - Sperling, Reisa Anne AU - Teunissen, Charlotte Elisabeth AU - Carrillo, Marı́a C. TI - Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup JO - Alzheimer s & Dementia VL - 20 IS - 8 SP - 5143 EP - 5169 PY - 2024 DA - 2024/06/27 DO - 10.1002/alz.13859 UR - https://doi.org/10.1002/alz.13859 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.